137 related articles for article (PubMed ID: 7828277)
1. No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma.
Bokemeyer C; Kynast B; Harstrick A; Laage E; Schmoll E; von Wussow P; Schmoll HJ
Cancer Chemother Pharmacol; 1995; 35(4):334-8. PubMed ID: 7828277
[TBL] [Abstract][Full Text] [Related]
2. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study.
Vitale FV; Romeo P; Vasta F; Panebianco V; Calì S; Rotondo S; Ferraù F; La Greca M
Anticancer Res; 2007; 27(6B):4077-81. PubMed ID: 18225574
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma.
Colleoni M; Buzzoni R; Bajetta E; Bochicchio AM; Bartoli C; Audisio R; Bonfanti G; Nolè F
Cancer; 1993 Dec; 72(11):3196-201. PubMed ID: 8242542
[TBL] [Abstract][Full Text] [Related]
4. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b.
Patt YZ; Yoffe B; Charnsangavej C; Pazdur R; Fischer H; Cleary K; Roh M; Smith R; Noonan CA; Levin B
Cancer; 1993 Nov; 72(9):2574-82. PubMed ID: 7691392
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
6. Treatment of unresectable hepatocellular carcinoma with a combination of human recombinant alpha-2b interferon and doxorubicin: results of a pilot study.
Lotz JP; Grange JD; Hannoun L; Boudghene F; Amiot X; Lamarque D; Andre T; Esteso A; Bellaiche A; Bouleuc C
Eur J Cancer; 1994; 30A(9):1319-25. PubMed ID: 7528030
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
8. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma.
Kardinal CG; Moertel CG; Wieand HS; Schutt AJ; O'Connell MJ; Wright K; Wiesenfeld M; Tschetter LK; Krook JE
Cancer; 1993 Apr; 71(7):2187-90. PubMed ID: 8384064
[TBL] [Abstract][Full Text] [Related]
9. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
Kim SJ; Seo HY; Choi JG; Sul HR; Sung HJ; Park KH; Choi IK; Oh SC; Yoon SY; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2006 Apr; 57(4):436-42. PubMed ID: 16049620
[TBL] [Abstract][Full Text] [Related]
10. Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC).
Kountouras J; Boura P; Karolides A; Zaharioudaki E; Tsapas G
Hepatogastroenterology; 1995 Feb; 42(1):31-6. PubMed ID: 7782031
[TBL] [Abstract][Full Text] [Related]
11. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
Uka K; Aikata H; Takaki S; Miki D; Jeong SC; Hiramatsu A; Kodama H; Shirakawa H; Kawakami Y; Takahashi S; Toyota N; Ito K; Chayama K
Liver Int; 2007 Nov; 27(9):1209-16. PubMed ID: 17919232
[TBL] [Abstract][Full Text] [Related]
12. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Ogura T; Hagihara A; Iwasa S
Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
[TBL] [Abstract][Full Text] [Related]
16. A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. The Gastrointestinal Tumor Study Group.
Cancer; 1990 Jul; 66(1):135-9. PubMed ID: 2162240
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma.
Feun LG; Savaraj N; Hung S; Reddy R; Jeffers L; Benedetto P; Livingstone AS; Ardalan B; Levi JU; Parker T
Am J Clin Oncol; 1994 Oct; 17(5):393-5. PubMed ID: 8092109
[TBL] [Abstract][Full Text] [Related]
18. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma.
Pohl J; Zuna I; Stremmel W; Rudi J
Chemotherapy; 2001; 47(5):359-65. PubMed ID: 11561139
[TBL] [Abstract][Full Text] [Related]
19. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Itokawa N; Atsukawa M; Tsubota A; Okubo T; Arai T; Nakagawa A; Kondo C; Iwakiri K
Int J Clin Oncol; 2016 Aug; 21(4):676-683. PubMed ID: 26701173
[TBL] [Abstract][Full Text] [Related]
20. [Prolonged partial remission of a hepatocellular carcinoma treated with adriamycin and recombinant human alpha-2 interferon].
Amiot X; Grangé JD; Boudghene F; Lamarque D; Lotz JP; Izrael V; Bodin F
Ann Gastroenterol Hepatol (Paris); 1991 Oct; 27(5):211-4. PubMed ID: 1660687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
